Tesamorelin has a more established evidence base, primarily in the context of HIV-associated lipodystrophy, where pivotal randomised controlled trials (including Falutz et al., NEJM, 2010) demonstrated statistically significant reductions in visceral adipose tissue
Safety: No toxic dose has been determined to date Study in rats with a single 20mg/kg IM dose, no deaths, abnormalities in body weight, food intake, or behavior noted Study in dogs at 10mg/kg IM showed no adverse effects Study in rats of 28 days of 0.2 mg, 1mg, or 4mg/day IM no changes relative to saline injection Study in dogs of 0.1 mg, 0.5 mg, or 2 mg/day IM no changes relative to saline injection Uses: Study: protection against NSAID and alcohol adverse effects Study: healing actions on wound and injuries from trauma and systemic issues Study: benefits in neuropsychiatric conditions like depression, though other studies show it has poor penetration of the blood brain barrier
Consistent with observations in Fig
Locations Choose from our three Seattle locations: Information